Get the Stockscreener App
446.40
0.71%
-3.18
After Hours:
446.40
Alnylam Pharmaceuticals Inc stock is traded at $446.40, with a volume of 814.45K.
It is down -0.71% in the last 24 hours and down -1.06% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$449.58
Open:
$453.045
24h Volume:
814.45K
Relative Volume:
0.72
Market Cap:
$58.51B
Revenue:
$2.46B
Net Income/Loss:
$-319.09M
P/E Ratio:
-180.73
EPS:
-2.47
Net Cash Flow:
$-52.09M
1W Performance:
-1.58%
1M Performance:
-1.06%
6M Performance:
+65.82%
1Y Performance:
+62.58%
1-Day Range:
$442.51
$453.05
1-Week Range:
$442.51
$462.88
52-Week Range:
$205.87
$484.21
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
446.40 | 58.93B | 2.46B | -319.09M | -52.09M | -2.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.74 | 97.91B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.90 | 58.88B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
711.62 | 43.52B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
326.06 | 36.11B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-04-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-04-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Mar-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
$1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth This Much Today - Benzinga
RNA-Based Therapies Industry Analysis 2025 | Growth, USA Market - openPR.com
Is Alnylam Pharmaceuticals (ALNY) an Undervalued Stock? - Yahoo
Does Alnylam Pharmaceuticals (ALNY) Have the Potential to Generate Strong Long-Term Growth? - Yahoo Finance
Cardiac Amyloidosis Pipeline 2025: Pioneering Clinical Developments by 20+ Global Leaders – DelveInsight | Featuring Eidos Therapeutics, Intellia Therapeutics, Novo Nordisk, Alnylam Pharmaceuticals - Barchart.com
Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Bannerman Wealth Management Group LLC Sells 565 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
IFM Investors Pty Ltd Acquires 1,508 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Assenagon Asset Management S.A. Purchases 11,281 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Swedbank AB Has $20.97 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $500.00 at Royal Bank Of Canada - MarketBeat
Pallas Capital Advisors LLC Decreases Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (ALNY): Evaluating Valuation After FDA Tightens Drug Advertising Disclosure Rules - simplywall.st
Alnylam at Bernstein Forum: Strategic Growth in RNAi Therapies - Investing.com
Alnylam at Bernstein Forum: Strategic Growth in RNAi Therapies By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Sumitomo Mitsui DS Asset Management Company Ltd - MarketBeat
RNA-based Therapies Market to Reach USD 213.54 Billion by 2033, Driven by Rare Diseases, Oncology, and Advances in RNA Technologies | DataM Intelligence - PR Newswire
With DTC ads under fire, pharma companies need to pivot - PharmaVoice
U.S. Capital Wealth Advisors LLC Sells 3,984 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $520.00 - MarketBeat
Gateway Investment Advisers LLC Decreases Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $566.00 at The Goldman Sachs Group - MarketBeat
Aug Volume: Is Alnylam Pharmaceuticals Inc impacted by rising ratesQuarterly Profit Summary & Free Verified High Yield Trade Plans - خودرو بانک
Nasdaq Moves: What’s the fair value of Alnylam Pharmaceuticals Inc. stock2025 Market Overview & Growth Oriented Trading Recommendations - خودرو بانک
Does Alnylam's Entry Into the Genomics Alliance Hint at a New Era for Illumina (ILMN) R&D? - Yahoo Finance
Swedbank AB Increases Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Fed Meeting: Is Alnylam Pharmaceuticals Inc impacted by rising ratesEarnings Miss & AI Powered Buy and Sell Recommendations - خودرو بانک
Performance Recap: Can Alnylam Pharmaceuticals Inc. be the next market leader2025 Top Gainers & Real-Time Chart Pattern Alerts - khodrobank.com
Strs Ohio Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Acadian Asset Management LLC Has $2.42 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
RBC Capital Initiates Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Announces Target Price $500 - 富途牛牛
Alnylam stock price target raised to $500 from $435 at RBC Capital - Investing.com India
Alnylam Pharmaceuticals Completes Phase 1 Study of ALN-AGT01 RVR - TipRanks
Moderna, Alnylam settle patent row over COVID vaccine delivery technology - MSN
RBC Capital Raises Alnylam Pharmaceuticals (ALNY) Price Target t - GuruFocus
Moderna (MRNA) Settles Patent Dispute with Alnylam - GuruFocus
RBC Raises Price Target on Alnylam Pharmaceuticals to $500 From $435, Keeps Outperform Rating - MarketScreener
Ascent Group LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $3.76 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
AG2R LA Mondiale Gestion D Actifs Buys New Shares in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Growth Review: What are analysts price targets for Alnylam Pharmaceuticals IncJuly 2025 Levels & Free Weekly Watchlist of Top Performers - khodrobank.com
Coagulation factor deficiency Market Analysis: Epidemiology Insights, Therapies, Companies, by DelveInsight | Novo Nordisk, Pfizer, Spark Therapeutics, Roche, Sanofi (Genzyme), Alnylam Pharmaceuticals - Barchart.com
Moderna settles Alnylam patent lawsuits over COVID vaccine technology - ET Pharma
Moderna settles Alnylam patent lawsuits over COVID vaccine technology | Business Information & News | FE - Westlaw Today
Moderna, Alnylam Agree to End Vaccine-Delivery Patent Lawsuits - Bloomberg Law News
Alnylam joins genomic alliance to advance RNA interference therapies - Investing.com India
Alnylam joins Alliance for Genomic Discovery to advance RNAi therapeutics - Drug Discovery News
Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine - The Malaysian Reserve
Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, ex - GuruFocus
Alnylam Pharmaceuticals Insiders Sold US$12m Of Shares Suggesting Hesitancy - Yahoo Finance
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):